Drugs / Anhydrous Enol-Oxaloacetate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05720624 | Oct 2025 | central nervous system cancer | Mayo Clinic | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04450160 | Dec 2020 → Jul 2022 | glioblastoma | MetVital, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anhydrous Enol-Oxaloacetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04450160 ↗ |
| Known as | AEO | “In the body, Anhydrous Enol-Oxaloacetate (AEO) converts into "Oxaloacetate", a metabolite important for many biochemical reactions in the body.” NCT04450160 ↗ |
| Route | Oral | “Oral supplementation with AEO along with the Standard of Care (Temozolomide)” NCT04450160 ↗ |